VEGF₁₂₁, is predictor for survival in activated B-cell-like diffuse large B-cell lymphoma and is related to an immune response gene signature conserved in cancers.

ABSTRACT: Tumor microenvironment including endothelial and immune cells plays a crucial role in tumor progression and has been shown to dramatically influence cancer survival. In this study, we investigated the clinical relevance of the gene expression of key mediators of angiogenesis, VEGF isoforms 121, 165, and 189, and their receptors (VEGFR-1 and R-2) in a cohort of patients (n = 37) with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) from the Collaborative Trial in Relapsed Aggressive Lymphoma (CORAL). In patients with ABC-like DLBCL, but not in patients with GCB-like DLBCL, low VEGF₁₂₁ expression was associated with a significantly better survival than in those with high VEGF₁₂₁ level: 4-year overall survival at 100% vs 36% (<

SUBMITTER: Broseus J 

PROVIDER: S-EPMC5710886 | biostudies-literature | 2017 Oct

REPOSITORIES: biostudies-literature